What BioSante's Balance Sheet Says About Future R&D [View article]
You have pointed out an important element in the GVAX story. Physicians have been supporting a variety of studies and trials related to GVAX and BioSante has benefited from that. While numerous, these studies are not the large, double-blinded, randomized clinical trials that are needed to impress FDA reviewers who might approve GVAX for commercial use. BioSante management is apparently looking at various options, including a strategic partner, to pay for those important clinical trials for GVAX. Unfortunately, this particular option means BioSante will have to give up some of the ownership or offer royalities. There is no free lunch in pharma.
What BioSante's Balance Sheet Says About Future R&D [View article]
What BioSante's Balance Sheet Says About Future R&D [View article]